The role of cytokines in the failing human heart.

[1]  H. Oral,et al.  Hemodynamic regulation of tumor necrosis factor-alpha gene and protein expression in adult feline myocardium. , 1997, Circulation research.

[2]  P. Ponikowski,et al.  Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. , 1997, Circulation.

[3]  J. A. Bowers,et al.  Role of cytokines in the mechanism of action of amlodipine: the PRAISE Heart Failure Trial. Prospective Randomized Amlodipine Survival Evaluation. , 1997, Journal of the American College of Cardiology.

[4]  P. Poole‐Wilson,et al.  Elevated soluble CD14 receptors and altered cytokines in chronic heart failure. , 1997, The American journal of cardiology.

[5]  M. Takemura,et al.  Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis, in patients with chronic congestive heart failure. , 1997, Journal of the American College of Cardiology.

[6]  G. MacGowan,et al.  Circulating interleukin-6 in severe heart failure. , 1997, The American journal of cardiology.

[7]  M. Satoh,et al.  Inducible nitric oxide synthase and tumor necrosis factor-alpha in myocardium in human dilated cardiomyopathy. , 1997, Journal of the American College of Cardiology.

[8]  C M O'Connor,et al.  Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. , 1996, The New England journal of medicine.

[9]  T. LeJemtel,et al.  Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. , 1996, Journal of the American College of Cardiology.

[10]  C. Lavie,et al.  The clinical relevance of circulating tumor necrosis factor-alpha in acute decompensated chronic heart failure without cachexia. , 1996, Chest.

[11]  B. Bozkurt,et al.  Basic mechanisms in heart failure: the cytokine hypothesis. , 1996, Journal of cardiac failure.

[12]  C. Long,et al.  Interleukin-1β Is a Negative Transcriptional Regulator of α1-Adrenergic Induced Gene Expression in Cultured Cardiac Myocytes* , 1996, The Journal of Biological Chemistry.

[13]  M. Yacoub,et al.  Tumour necrosis factor and inducible nitric oxide synthase in dilated cardiomyopathy , 1996, The Lancet.

[14]  H. Oral,et al.  Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). , 1996, Journal of the American College of Cardiology.

[15]  M. Munger,et al.  Circulating concentrations of proinflammatory cytokines in mild or moderate heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. , 1996, The American journal of cardiology.

[16]  D. Mann,et al.  Tumor Necrosis Factor-α and Tumor Necrosis Factor Receptors in the Failing Human Heart , 1996 .

[17]  K. Shiota,et al.  Targeted disruption of gp130, a common signal transducer for the interleukin 6 family of cytokines, leads to myocardial and hematological disorders. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[18]  O. Febo,et al.  Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. , 1995, Circulation.

[19]  D. Mann,et al.  Expression and functional significance of tumor necrosis factor receptors in human myocardium. , 1995, Circulation.

[20]  A. Takeshita,et al.  Monocyte-related cytokines in acute myocardial infarction. , 1995, American heart journal.

[21]  F. Neumann,et al.  Cardiac release of cytokines and inflammatory responses in acute myocardial infarction. , 1995, Circulation.

[22]  M. Gómez-Lechón,et al.  Cytokine signaling during myocardial infarction: sequential appearance of IL-1 beta and IL-6. , 1995, The American journal of physiology.

[23]  N. Takahashi,et al.  Interleukin-1 beta modulates the growth and phenotype of neonatal rat cardiac myocytes. , 1995, The Journal of clinical investigation.

[24]  D. Mann,et al.  Tumor necrosis factor-alpha gene and protein expression in adult feline myocardium after endotoxin administration. , 1995, The Journal of clinical investigation.

[25]  C. Long,et al.  Interleukin-1 beta induces cardiac myocyte growth but inhibits cardiac fibroblast proliferation in culture. , 1995, The Journal of clinical investigation.

[26]  H. Cohen,et al.  Tumor necrosis factor, natural killer activity and other measures of immune function and inflammation in elderly men with heart failure. , 1995, Gerontology.

[27]  A. Matsumori,et al.  Increased circulating cytokines in patients with myocarditis and cardiomyopathy. , 1994, British heart journal.

[28]  T. LeJemtel,et al.  Pathophysiological Correlates of Increased Serum Tumor Necrosis Factor in Patients With Congestive Heart Failure: Relation to Nitric Oxide‐Dependent Vasodilation in the Forearm Circulation , 1994, Circulation.

[29]  M. Kinoshita,et al.  Relation between endothelin-1 spillover in the lungs and pulmonary vascular resistance in patients with chronic heart failure. , 1994, Journal of the American College of Cardiology.

[30]  D. Mann,et al.  Basic mechanisms in congestive heart failure. Recognizing the role of proinflammatory cytokines. , 1994, Chest.

[31]  A. Thomson.  The cytokine handbook , 1994 .

[32]  T. Sakamoto,et al.  Elevated plasma interleukin-6 levels in patients with acute myocardial infarction. , 1993, American heart journal.

[33]  M. Herold,et al.  Increased levels of serum neopterin and decreased production of neutrophil superoxide anions in chronic heart failure with elevated levels of tumor necrosis factor-alpha. , 1993, Journal of the American College of Cardiology.

[34]  L. Baud,et al.  Tumor necrosis factor-induced contraction of cultured rat mesangial cells: interaction with angiotensin II. , 1993, The Journal of laboratory and clinical medicine.

[35]  P. Zabel,et al.  Effects of Pentoxifylline on Circulating Cytokines (TNF and IL-6) in Severe Pulmonary Tuberculosis , 1993 .

[36]  A. Pardee,et al.  Pentoxifylline decreases tumor necrosis factor expression and serum triglycerides in people with AIDS. NIAID AIDS Clinical Trials Group. , 1993, Journal of acquired immune deficiency syndromes.

[37]  A. Maisel,et al.  Immune function in patients with chronic stable congestive heart failure. , 1993, American heart journal.

[38]  B. Spiegelman,et al.  Through thick and thin: Wasting, obesity, and TNFα , 1993, Cell.

[39]  P. Zabel,et al.  Inhibition of endogenous TNF formation by pentoxifylline. , 1993, Immunobiology.

[40]  M. Packer.  How should physicians view heart failure? The philosophical and physiological evolution of three conceptual models of the disease. , 1993, The American journal of cardiology.

[41]  W. Fiers,et al.  Tumor necrosis factor : molecular and cellular biology and clinical relevance , 1993 .

[42]  T. Billiar,et al.  Tumor necrosis factor alpha inhibits hepatocyte mitochondrial respiration. , 1992, Annals of surgery.

[43]  J. H. Johnson,et al.  The tissue distribution of tumor necrosis factor biosynthesis during endotoxemia. , 1992, The Journal of clinical investigation.

[44]  F. Pagani,et al.  Left ventricular systolic and diastolic dysfunction after infusion of tumor necrosis factor-alpha in conscious dogs. , 1992, The Journal of clinical investigation.

[45]  M. Packer.  The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. , 1992, Journal of the American College of Cardiology.

[46]  U. Ikeda,et al.  Serum interleukin 6 levels become elevated in acute myocardial infarction. , 1992, Journal of molecular and cellular cardiology.

[47]  D. Wallach,et al.  Cytoplasmic truncation of the p55 tumour necrosis factor (TNF) receptor abolishes signalling, but not induced shedding of the receptor. , 1992, The EMBO journal.

[48]  M. Entman,et al.  Neutrophil adherence to isolated adult cardiac myocytes. Induction by cardiac lymph collected during ischemia and reperfusion. , 1992, The Journal of clinical investigation.

[49]  D. Wallach,et al.  Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors , 1992, The Journal of experimental medicine.

[50]  J. McMurray,et al.  Increased concentrations of tumour necrosis factor in "cachectic" patients with severe chronic heart failure. , 1991, British heart journal.

[51]  K. Sell,et al.  Abnormal expression of histocompatibility and mitochondrial antigens by cardiac tissue from patients with myocarditis and dilated cardiomyopathy. , 1991, The American journal of pathology.

[52]  Robert C. Thompson,et al.  Interleukin-1 receptor antagonist reduces mortality from endotoxin shock , 1990, Nature.

[53]  G. Schreiner,et al.  Mechanism of cytokine inhibition of beta-adrenergic agonist stimulation of cyclic AMP in rat cardiac myocytes. Impairment of signal transduction. , 1990, Circulation research.

[54]  H. Fillit,et al.  Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. , 1990, The New England journal of medicine.

[55]  J. Dayer,et al.  Purification and characterization of a 26‐kDa competitive inhibitor of interleukin 1 , 1990, European journal of immunology.

[56]  D. Hossfeld,et al.  TNF-induced cardiomyopathy , 1990, The Lancet.

[57]  D. Wallach,et al.  Two tumor necrosis factor-binding proteins purified from human urine. Evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors. , 1990, The Journal of biological chemistry.

[58]  J E Parrillo,et al.  A prospective, randomized, controlled trial of prednisone for dilated cardiomyopathy. , 1989, The New England journal of medicine.

[59]  M. Singer,et al.  TUMOUR NECROSIS FACTOR IN BRONCHOPULMONARY SECRETIONS OF PATIENTS WITH ADULT RESPIRATORY DISTRESS SYNDROME , 1989, The Lancet.

[60]  J. Kovacs,et al.  The cardiovascular response of normal humans to the administration of endotoxin. , 1989, The New England journal of medicine.

[61]  J. Lancaster,et al.  Inhibition of target cell mitochondrial electron transfer by tumor necrosis factor , 1989, FEBS letters.

[62]  E. Nilsson,et al.  Isolation and characterization of a tumor necrosis factor binding protein from urine , 1989, European journal of haematology.

[63]  C. Natanson,et al.  Endotoxin and tumor necrosis factor challenges in dogs simulate the cardiovascular profile of human septic shock , 1989, The Journal of experimental medicine.

[64]  B. Beutler,et al.  The biology of cachectin/TNF--a primary mediator of the host response. , 1989, Annual review of immunology.

[65]  I. Goldenberg,et al.  Autoantibodies against beta-adrenoceptors in human idiopathic dilated cardiomyopathy. , 1989, Circulation research.

[66]  S. H. Socher,et al.  Recombinant human tumor necrosis factor induces acute reductions in food intake and body weight in mice , 1988, The Journal of experimental medicine.

[67]  J. Lowenthal,et al.  A urine inhibitor of interleukin 1 activity that blocks ligand binding. , 1987, Journal of immunology.

[68]  A. Oliff,et al.  Tumors secreting human TNF/cachectin induce cachexia in mice , 1987, Cell.

[69]  J. Tavernier,et al.  Multiple effects of tumor necrosis factor on lipoprotein lipase in vivo. , 1987, The Journal of biological chemistry.

[70]  M. Rosenblum,et al.  Phase I study of recombinant tumor necrosis factor in cancer patients. , 1987, Cancer research.

[71]  R. Gerli,et al.  Immunologic studies of peripheral blood from patients with idiopathic dilated cardiomyopathy. , 1986, American heart journal.

[72]  B. Beutler,et al.  Cachectin/tumor necrosis factor: production, distribution, and metabolic fate in vivo. , 1985, Journal of immunology.

[73]  M Sakamoto,et al.  Alpha-human atrial natriuretic polypeptide is released from the heart and circulates in the body. , 1985, Biochemical and biophysical research communications.

[74]  B. Maisch,et al.  Demonstration of organ specific antibodies against heart mitochondria (anti-M7) in sera from patients with some forms of heart diseases. , 1984, Clinical and experimental immunology.

[75]  J. Carlquist,et al.  DEFICIENT NATURAL KILLER CELL ACTIVITY IN PATIENTS WITH IDIOPATHIC DILATED CARDIOMYOPATHY , 1982, The Lancet.

[76]  C. Leier,et al.  Drug-induced conditioning in congestive heart failure. , 1982, Circulation.

[77]  R. Magorien,et al.  Long-term benefit of dobutamine in patients with congestive cardiomyopathy. , 1980, American heart journal.

[78]  M. Morrell,et al.  ABSORPTION OF PENTAGASTRIN FROM GASTROINTESTINAL TRACT IN MAN , 1975, The Lancet.

[79]  V. Schuermans,et al.  IMPAIRED NEUTROPHIL PHAGOCYTOSIS , 1974 .